

**Prospectively Validated Pre-Operative Prediction of Weight and Co-Morbidity Resolution in Individual Patients Comparing Five Bariatric Operations**

Gus J Slotman, M.D.

Department of Surgery

5        Inspira Health Network

Vineland, NJ

Address for Correspondence:

Gus J Slotman, M.D, FACS, FCCM, FCCP, FASMBS

10     Director of Clinical Research

Inspira Health Network

1505 West Sherman Avenue

Suite B

Vineland, NJ 08360

15     Telephone: 856-641-8635

FAX: 856-641-8636

Email: [slotmang@ihn.org](mailto:slotmang@ihn.org)

Word count: 2,454

Running title: Predicting outcomes after bariatric surgery

20     Acknowledgements: Supported, in part, by a research grant from the Lourdes Foundation, Camden, NJ

Presented, in part, at Obesity Week, November 11-16, 2013, Atlanta, GA

**ABSTRACT**

**Background:** No method predicts, pre-operatively, post-operative bariatric surgery outcomes in individual patients. Decisions for/against surgery and operation choice remain subjective. Only 1% of qualifying patients embrace bariatric surgery.

30 **Objective:** To predict pre-operatively, and validate prospectively, weight and co-morbidity resolution in individual patients after open (RYGB) and laparoscopic (LRYGB) gastric bypass, laparoscopic adjustable gastric band (LAGB), sleeve gastrectomy (SG), and bilio-pancreatic diversion/duodenal switch (BPD/DS).

**Design:** Retrospective analysis

35 **Setting:** Surgical Review Corporation BOLD database, 2007-2010

**Participants:** 166,601 patients who had RYGB (n=5,389), LRYGB (n=83,059), LAGB (n=67,514), SG (n=8,966), or BPD/DS (n=1,673)

**Interventions:** None

**Main Outcomes and Measures:** Patients were randomized into modeling (n=124,053) and  
40 validation (n=42,548) groups. From pre-operative data, multivariate linear and logistic regression predicted weight and co-morbidities at 2, 6, 12, 18, and 24 months post-operatively. Model fit was examined by r-squared and ROC/AUC and predicted versus observed results via Pearson correlation coefficient and Sensitivity/Specificity.

**Results:** Follow-up at 2/24 months was 120,909/11,014 for Modeling and 41,528/3,703 for  
45 Validation. Weight models r-squared was 0.910, 0.813, 0.725, 0.638, and 0.613 at 2, 6, 12, 18,  
and 24 months, respectively. Categorical ROC/AUC was 0.617 to 0.949 for 24 month  
predictions. Continuous Pearson Coefficients were 0.969/0.811 at 2/24 months. Co-morbidity  
resolution median 24 month Sensitivity/Specificity were 79.2%/ 97.42%.

**Conclusions:** Prospectively validated pre-operative models predict, in individual patients,  
50 weight and obesity co-morbidities two years in advance for RYGB, LRYGB, LAGB, SG or BPD/DS.  
This advance knowledge facilitates choosing which operation is best for each individual and  
may encourage more patients to choose bariatric surgery.

55

**Introduction:** Morbid obesity affects 6.3% of the US population,<sup>(1, 2)</sup> with weight-related  
medical problems doubling their medical expenses.<sup>(3)</sup> From the 2012 US Census,<sup>(4)</sup> over 19.8  
60 million Americans meet NIH criteria for bariatric surgery.<sup>(5)</sup> Nevertheless, only about 0.97% of  
those who qualify for bariatric operations actually undergo surgery <sup>(6)</sup> and benefit from its  
weight loss and resolution of co-morbidities.<sup>(7)</sup> The relative efficacy of different operations may

be debated,<sup>(8)</sup> but the minimal penetration of bariatric surgery into the morbidly obese population leaves millions disabled. Characteristics of operative patients are understood,<sup>(9)</sup> but why patients decide against bariatric surgery remains unknown. Certainly variation in health insurance coverage for bariatric surgery and accompanying financial concerns are contributing factors<sup>(10)</sup>. Patient lack of knowledge and concerns over outcomes and complications may contribute.<sup>(11, 12)</sup> Among obese patients who declined bariatric surgery, Fung and associates found fear of complications (51%), not needing weight loss surgery (32%), fear of surgery (24%), and costs (20%) to be the principal reasons against operation<sup>(13)</sup>. The open question is how to calm those concerns and encourage more patients to embrace surgical weight loss.

The lack of validated outcomes predictions for individual morbidly obese patients may be another factor that discourages patients from having weight loss surgery. Calculators predicting the relatively rare complications of bariatric surgery<sup>(14,15,16)</sup> and non-validated weight loss calculators<sup>(17)</sup> are reported. Nevertheless, prospectively validated predictions for bariatric surgery, applicable to individuals and comparing future results of the most common operations are not available. Thus, in counseling patients about bariatric surgery, physicians can reference only the published results for each operation, not individual outcomes. Ultimately, the choice of whether or not to have weight loss surgery, and which procedure to undergo, are left, subjectively, to the patient.

The present study hypothesized that the Systemic Mediator Associated Response Test (SMART) methodology could predict individual bariatric surgery outcomes from pre-operative clinical data. Previous, SMART models predicted qualitative and quantitative results in septic patients,

(18) and identified cohorts within failed clinical trials among which study drugs reduced septic  
85 mortality. (19) The objective of the present study, then, was to determine whether or not  
outcomes from the most frequently performed bariatric operations could be predicted in  
individual patients from pre-operative data, and then validated prospectively in a separate  
population.

90 **Methods:** With the approval of the Data Access Committee of the Surgical Review Corporation  
(SRC) and of the Institutional Review Board of Our Lady of Lourdes Medical Center, Camden,  
N.J., HIPAA-compliant data from the SRC's Bariatric Outcomes Longitudinal Database (BOLD) (20)  
on 166,601 patients who had undergone primary bariatric surgery between June 1, 2007 and  
December 31, 2010, and who had had at least one post-operative follow-up visit was analyzed.  
95 Business and validation rules were built into BOLD to flag or reject potential errors at the point  
of data entry, as well as automated data quality reports to identify unacceptable trends after  
data capture. In addition, pre-operative data, post-operative complications, and deaths  
entered into BOLD were verified 100% on-site by SRC monitors. Long term follow-up  
information was verified by random chart reviews in at least 15% of the cases.(20) Revisional  
100 operations were excluded from the present study. In the overall population, 5,389 patients  
underwent RYGB, 83,059 had LRYGB, 8,966 received SG, 67,514 had LAGB, and 1,673 had  
BPD/DS (BPD and BPD/DS combined). Subjects were randomized into a modeling group (n =  
124,053) or a validation group (n = 42,548). Pre-operative BOLD parameters with <5% missing  
data (n=46) were screened as independent variables. Categorical pre-operative variables sub-

105 categorized by severity of illness in BOLD using semi-numerical scales of 1 to 5 or 1 to 4, etc.  
were included in the statistical mix. Continuous dependent variables included weight and  
weight loss. Dichotomous dependent variables included diabetes mellitus, hypertension,  
obstructive sleep apnea (OSA), liver disease, cholelithiasis, gastro-esophageal reflux disease  
(GERD), congestive heart failure (CHF), abdominal hernia, surgeon/support group follow-up and  
110 adverse events, as defined by the Surgical Review Corporation's BOLD reporting definitions. <sup>(20)</sup>  
From a General Estimating Equation platform, multivariate linear regression identified pre-  
operative independent variables that predicted weight and weight loss at 2, 6, 12, 18 and 24  
months for each operation. Multivariate logistic regression identified pre-operative  
independent parameters predicting co-morbidities at 2, 6, 12, 18 and 24 months for each  
115 operation, and adverse events at 0-6, and 0-12 months. All models were built using forward  
selection. Only independent variables with interaction coefficients  $p < 0.10$  were included in the  
models. Low-incidence variables causing quasi-complete separation of data points were not  
used. The coefficient of determination ( $r^2$ ) tested model fit for continuous dependent  
variables. Receiver Operating Characteristics/Area Under the Curve (ROC/AUC) examined  
120 dichotomous model fit. <sup>(21)</sup> Modeling was performed for each operation for each dependent  
variable at each observation point.

Linear models were tested by comparing validation group predicted values to the observed  
outcomes using Pearson correlation coefficients. Logistic models were validated by sensitivity  
and specificity. <sup>(21)</sup>

125

**Results:** Pre-operative variables that were screened as weighted independent variables (n=46) and those included in the final prognostic models (n=26) are listed in Table 1.

Model fit for continuous and dichotomous dependent variables and validation results are displayed in Table 2. For weight/weight loss,  $r^2$  values were 0.910, 0.813, 0.725, 0.638, and 0.613 in baseline models that predicted these continuous dependent variables at 2, 6, 12, 18, and 24 months post-operatively, respectively. ROC AUC for dichotomous dependent variables ranged from 0.985 for cholelithiasis at 2 months to 0.599 for Surgeon Follow-up/Support group attendance at 12 months. Models for the complications of nausea and vomiting, intra-abdominal complications, and organ failure and sepsis were not successful because low event rates caused a quasi-separation of points. Grouping all occurrences of these adverse events into an Any AE category resulted in an ROC AUC of 0.683 for both the 0-6 month and 6-12 month periods.

Weight/weight loss models were validated at 2, 6, 12, 18, and 24 months after surgery with Pearson Correlation Coefficients of 0.959, 0.932, 0.875, 0.837, and 0.811, respectively. Validation of dichotomous models included median sensitivity of 79.2% (range 25.0% to 98.30%) and median specificity of 97.42%% (range 80.27% to 99.99%). For Any Adverse Event,

specificity for both 0-6 months and 6-12 months was 99.92% but sensitivity was only 0.52% and 0.51%, respectively, for those intervals.

150

155

**Discussion:** This investigation describes a method that predicts, from pre-operative clinical data, in individual patients, what weight/weight loss and the presence or absence of the most serious obesity co-morbidities will be up to twenty-four months in advance following RYGB, LRYGB, LAGB, SG, or BPD/DS. These results individualize the choice of bariatric operation for morbidly obese patients. Weight/weight loss were validated at clinically useful accuracy. Diabetes mellitus was predicted with a 24 month specificity of 93.97%, and clinically applicable sensitivities. Hypertension prognostications had consistently high sensitivity/specificity. Obstructive sleep apnea models achieved specificities greater than 90% through 24 months. Pre-operative predictions of liver disease also carried strong validation results, as did cholelithiasis models through 24 months. Presence/absence of GERD was forecast well from pre-operative data. Abdominal hernia models had excellent sensitivity and specificity. In spite of high specificities, low event rates for congestive heart failure, any adverse event, and surgeon follow-up/support group attendance limited sensitivity in those models. Our review of



the literature indicates that the prospectively validated predictions of weight/weight loss and of  
170 the presence or resolution of obesity co-morbidities in individual patients described here,  
comparing results from five different operations, have not been reported previously and  
represent a significant advance in the field of bariatric surgery. These predictive engines will  
enable physicians and morbidly obese patients to individualize objectively the choice of  
bariatric operation.

175  
While previous reports described clinical formulae, <sup>(22)</sup> quartile regression curves, <sup>(23)</sup> artificial  
neural networks, <sup>(24)</sup> and other correlations <sup>(25)</sup> to predict weight/weight loss, most applied to  
only one operation, were not validated prospectively, and used databases less comprehensive  
for each patient a pre-operative baseline than BOLD. Baseline weight/weight loss models in the  
180 present investigation achieved Pearson correlation coefficients of 0.959, 0.932, 0.875, 0.837,  
and 0.811 at 2, 6, 12, 18, and 24 months post-operative, respectively. The results here, for the  
first time, enable data-based, individualized choice of weight loss operation.

Type II diabetes mellitus afflicts 28-52% of bariatric patients, <sup>(26, 27)</sup> and improves with weight  
185 loss. <sup>(28, 29)</sup> Knowing, in addition, what diabetes resolution will be comparing five operations  
could increase patients' confidence in choosing bariatric surgery. In the current analysis, Type II  
diabetes in individual patients was predicted accurately up to 24 months in advance. Diabetes  
sensitivity ranged from 98% to 60%, with specificity consistently above 91%. Previous studies  
associated diabetes control with post-operative weight loss, <sup>(28)</sup> and various clinical parameters,

190 but did not predict individual outcomes. <sup>(29)</sup> The prognostic models reported here enable Type II diabetes patients to know what their relative risk of diabetes persistence/resolution will be following bariatric surgery up to 24 months in advance, comparing future results from five weight loss operations.

195 Arterial hypertension resolves frequently following bariatric surgery. <sup>(30, 31)</sup> However, prior to the present investigation, remission or persistence of hypertension after any weight loss procedure was not predicted, but, rather, only associated statistically with baseline parameters and post-operative weight loss. <sup>(30, 31)</sup> In the current report, prospectively validated models predicted the risk of hypertension for individual patients up to 24 months in advance,  
200 comparing outcomes for RYGB, LRYGB, SG, LAGB and BPD/DS. Sensitivity/specificity were 92.44%/85.21% at 2 months and 79.56%/79.3% at 24 months. These models will enable individual hypertensive patients to choose objectively which procedure will control her/his high blood pressure most effectively.

205 Obstructive sleep apnea affects more than 40% of bariatric patients, <sup>(27)</sup> and often resolves following weight loss surgery. <sup>(32)</sup> However, post-operative outcomes predictions do not apply to individuals. Models that predicted OSA in the present paper performed well, with all ROC/ACU values 0.827 and higher, and sensitivity/specificity ranging from 73.99%/93.6% at 2 months, to 50.76%/90.95% at 24 months. Our review of the literature indicates that such

210 validated advance knowledge of OSA persistence/resolution in individual bariatric surgery patients has not been reported previously, and is an important finding of this study.

Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis involve 7-16% of bariatric surgery patients. <sup>(26, 27)</sup> While liver disease may resolve with weight loss, results vary between  
215 RYGB, LRYGB, LAGB, SG, and BPD/DS (31), adding decisional uncertainty for patients regarding which operation to undergo. For these patients, the liver disease models presented here add objectivity to the choice of bariatric procedure, with median sensitivity/specificity at 84.79%/98.41%. Thus, although the diagnosis of liver disease in BOLD was clinical only, as liver biopsies were not required on all patients, the prognostic models here provide individual  
220 weight-related liver dysfunction patients with clinically significant guidance regarding its resolution by operation type.

At surgery, 9-31% of bariatric patients have gallstones, <sup>(26, 27)</sup> and the incidence increases with post-operative weight loss. <sup>(33)</sup> However, pre-operative factors that predict the incidence of  
225 cholelithiasis following weight loss operations are not established. In this investigation, pre-operative cholelithiasis models were validated at sensitivity/specificity above 86.93%/97.21% through 24 months, providing a reliable means of identifying patients most at risk for gallstone formation. This advance knowledge could facilitate the decision of whether or not to perform incidental cholecystectomy at the time of primary bariatric surgery, or, for high risk patients  
230 without gallstones at operation, medical prophylaxis.

GERD is diagnosed pre-operatively in 35-52% of patients who undergo bariatric surgery. <sup>(26, 27)</sup>

Resolution of GERD is excellent with RYGB/LRYGB, and DS, variable with LAGB, but GERD may increase following SG. <sup>(34)</sup> Our review of the literature suggests that the present investigation is

235 the first to predict relative risk of GERD in individual patients after weight loss procedures.

While sensitivity drifted below 50% at 12 months, specificity actually increased in the 12-24 month models. Considering the inter-procedure variation of bariatric surgeries regarding post-operative GERD, the advance knowledge presented in this study may enable patients to compare the GERD effects of each technique in their individual cases.

240

At least 8% of bariatric surgery patients have pre-existing inguinal and ventral abdominal wall hernias. How and when to repair these defects continues to be debated. However, the incidence of abdominal hernia can increase following bariatric surgery to 50% and higher <sup>(33)</sup>

The prognostic models reported here provide patients and surgeons reliable pre-operative  
245 predictions of abdominal hernia development in individuals, comparing the five most common weight loss procedures. With ROC/AUC's all 0.921 and higher, and sensitivity/specificity consistently at clinically useful levels, these findings can facilitate objective pre-operative bariatric surgery planning regarding relative risk of abdominal hernia.

250

Congestive heart failure affects up to 9% of bariatric surgery patients pre-operatively. <sup>(26)</sup>

Although weight loss logically should ameliorate CHF severity, the rate of CHF following bariatric surgery can increase to over 22%. <sup>(33)</sup> The ability to identify before surgery the individuals most

at risk for CHF months and years after weight loss operations certainly could assist in pre-  
255 operative planning and peri-surgical management. In the present work, CHF ROC/AUC model  
fit was excellent. However, although specificity was above 99%, low event rates kept  
sensitivities in the 40% range and below. Nevertheless, these results are the first reported  
predictions of CHF in bariatric surgery.

260 Close long-term follow-up with bariatric surgeons and staff and regular support group  
attendance help to optimize surgical outcomes. In the present investigation, pre-operative  
modeling ROC/AUC's were 0.620 and under, Specificity was above 99%, but Sensitivity was  
<1%. In this modeling, then, one knows before surgery who will not follow-up, but not who are  
the compliant patients. Perhaps this at least identifies pre-operatively patients who need the  
265 most encouragement for follow-up compliance.

Modeling for adverse events yielded ROC/AUC of 0.683, high Specificity, and Sensitivity less  
than 1%, leaving the identities of problem-free patients clear, but not those at highest risk of  
complications. Fortunately, complications after bariatric surgery have been addressed by  
270 previous authors. Sarela et al developed the Obesity Surgery Mortality Risk Score, which  
predicts operative mortality. <sup>(14)</sup> Maciejewski and co-authors stratified mortality risk for  
gastric bypass. <sup>(8)</sup> Ramanan et al <sup>(15)</sup> developed a validated bariatric surgery mortality risk  
calculator, and Gupta and co-authors <sup>(16)</sup> generated a morbidity risk calculator, both of which

are available online: <http://www.surgicalriskcalculator.com/bariatric-surgery-risk-calculator>.

275 These clinical aides complement the prognostic models described in the present study.

A practical hypothetical demonstration of the outcomes models described here as applied to individual patients may be illustrative. In this clinical example, consider a 50 year-old Caucasian female who is 5ft.4in.tall, weighs 320 lbs., is employed full-time, drinks socially, takes ibuprofen for back and musculoskeletal pain, has stress urinary incontinence occasionally, has OSA, and  
280 takes antidepressants, proton pump inhibitors for GERD, one medication for hypertension, and oral agents for Type II diabetes. She does not have angina, asthma, CHF, cholelithiasis, liver disease, obesity hypoventilation syndrome, psychologic impairment, pulmonary hypertension, abdominal hernia, or other mental health diagnoses. This baseline information was entered into the prognostic models, and the program provided outcomes predictions of weight and  
285 relative risk of abdominal hernia, CHF, cholelithiasis, GERD, diabetes, hypertension, liver disease, and surgeon follow-up/support group attendance. Predicted outcomes for this patient are listed in Table 3.

To be clear, the prognostic models in this report use pre-operative clinical data, without laboratory or radiology results, to predict outcomes for individual morbidly obese patients,  
290 within the validation predicted versus observed statistical analyses presented, that would result if individuals were to choose RYGB or LRYGB or AGB or SG or BPD/DS. Prediction of the relative probability of a patient choosing one bariatric surgery approach over another was not attempted, as no database, including BOLD, can support statistical modeling for the ultimately subjective choices individuals make for their healthcare. Similarly, comparing statistically the

295 outcomes following one operation versus another was not part of this study. Results variation  
among these procedures have been well-described in the literature<sup>(5-9)</sup>. The concept underlying  
the present investigation was that pre-operative clinical characteristics of morbidly obese  
patients could be linked statistically to known bariatric surgery outcomes in the Modeling  
cohort, and that the accuracy of those models could be validated in a separate, similar  
300 population. The goal thus achieved was to give morbidly obese individuals and their healthcare  
providers additional advance knowledge of what outcomes could be for them if they were to  
choose one of the operations analyzed.

There are several limitations to this study. Firstly, the definitions of obesity co-morbidities in  
BOLD were entirely clinical. For example, that liver biopsies were not performed universally  
305 may have made the BOLD data incomplete academically. Secondly, BOLD contains no pre-  
operative laboratory or radiology information, all of which might have facilitated even more  
accurate predictive models. However, as a serendipitous benefit, the data on which the models  
here were based comprises common clinical information that enables every patient to benefit  
from the bariatric surgery prognostications presented. Thirdly, the decrease in follow-up  
310 patient visits over time may have contributed to sub-optimal modeling/validation for some  
conditions. Finally, the possible inconsistencies of a retrospective analysis on a prospectively  
collected database apply, which was the rationale for randomizing the entire BOLD population  
into Modeling and Validation databases at the beginning of this study.

315 **Conclusions:** Statistical models in this investigation provide individual morbidly obese patients clinically usable predictions of what weight and relative risk of the presence/absence of diabetes, hypertension, OSA, liver disease, cholelithiasis, GERD, and abdominal hernia would be up to 24 months in advance, comparing results from RYGB, LRYGB, LAGB, SG, and BPD/DS. Such advance knowledge may help facilitate optimized bariatric surgery outcomes. The clinical

320 predictions described here are intended to supplement the knowledge and judgment of bariatric surgeons in recommending the best operation for each patient. Certainly medical and anatomical conditions can render the predicted best procedure for individual patients from these models suboptimal for her/him. In addition, it may be that, in spite of this objective advance knowledge and the surgeon's counseling, some patients still will choose bariatric

325 procedures that are not optimal for them. For example, although Schauer and co-investigators reported superiority of LRYGB over SG in controlling Type 2 diabetes<sup>(35)</sup>, in the current wave of public popularity for SG, the latter may be chosen in spite of the published data. Also, some patients who could benefit from bariatric surgery still might not choose operative treatment of their obesity even with the individualized pre-operative outcomes predictions afforded by this

330 research, as, ultimately, it remains a personal, individual decision. Nevertheless, in the net effect, one hopes that the new predictive methodology presented here will become accessible to patients and physicians so that it might facilitate optimized patient care and, possibly, thereby may encourage more morbidly obese patients to embrace the benefits of weight loss surgery. The next step in this research, then, is to identify and engage formats that will enable

335 utilization of the predictive models described in this report, so as to put into practice the clinical benefits for which they were developed.



**Disclosure:** The author has no disclosures.

340

**References:**

3451. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents and adults, 1999--2002. *JAMA* 2004;291:2847--50.
2. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999--2010. *Journal of the American Medical Association*. 2012; 307(5):491-97
3503. Arterburn DE<sup>1</sup>, Maciejewski ML. Impact of morbid obesity on medical expenditures in adults. *J.Int J Obes (Lond)*. 2005 29(3):334-9.
4. <http://www.census.gov/popclock/>
5. Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement. *Am J Clin Nutr* 1992;55(2Suppl.):615S-619S

3556. Ponce J, Nguyen N, Hutter M, Sudan R, Morton JM. American Society for Metabolic and Bariatric Surgery estimation of bariatric procedures in the United States, 2011-2014. *SOARD* 2015. 11: 1199-1200
7. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. Bariatric Surgery A Systematic Review and Meta-analysis *JAMA*. 2004;292(14):1724-1737.
3608. Maciejewski ML, Arterburn DE, Cost-effectiveness of Bariatric Surgery *JAMA*. 2013; 310(7):742-743.
9. Jakobsen GS, Hofso D, Roislien J, Sandbu R, Hjelmessaeth J. Morbidly Obese Patients—Who Undergoes Bariatric Surgery? *Obes Surg*. 2010 20(8): 1142–1148
10. Lee J, Sheer J, Lopez N, Rosenbaum S. Coverage of Obesity Treatment: A State-by-State Analysis of Medicaid and State Insurance Laws. *Public Health Rep*. 2010 Jul-Aug; 125(4): 596–604
11. Maciejewski ML, Winegar DA, Farley JL. Risk stratification of serious adverse events after gastric bypass in the Bariatric Outcomes Longitudinal Database. *Surgery for Obesity and Related Diseases* 8 (2012) 671–678
37012. Afonso BB<sup>1</sup>, Rosenthal R, Li KM, Zapatier J. Perceived barriers to bariatric surgery among morbidly obese patients. *Surg Obes Relat Dis*. 2010 6(1):16-21
13. Fung M, Wharton S, Macpherson A, and Kuk J. Receptivity to Bariatric Surgery in Qualified Patients *Journal of Obesity* Volume 2016 (2016), Article ID 5372190, 6 pages
14. Sarela AI, Dexter AS, McMahon MJ. Use of the Obesity Surgery Mortality Risk Score to Predict Complications of Laparoscopic Bariatric Surgery. *OBES SURG* (2011) 21:1698–1703.
- 375

15. Ramanan B, Gupta PK, Gupta H, et al. Development and Validation of a Bariatric Surgery Mortality Risk Calculator Surg 2012;214:892–900.
16. Gupta PK, Franck C, Miller WJ. Development and Validation of a Bariatric Surgery Morbidity Risk Calculator Using the Prospective, Multicenter NSQIP Dataset J Am Coll Surg 2011;212:301–  
380 309.
17. Campos GM, Rabl C, MD, Mulligan K. Factors Associated With Weight Loss After Gastric Bypass Arch Surg. 2008;143(9):877-884
18. Slotman GJ: Prospectively validated prediction of physiologic variables and organ failure in septic patients: The Systemic Mediator Associated Response Test (SMART). Crit Care Med  
385 2002; 30:1035-1045
19. Slotman GJ: The systemic mediator-associated response test (SMART) identifies patients in failed sepsis clinical trials among whom novel drugs reduce mortality. J. Trauma 2011; 71(5):1406-14
20. DeMaria EJ, Pate, Warthen M., Winegar DA. Baseline data from American Society for Metabolic  
390 and Bariatric Surgery-designated Bariatric Surgery Centers of Excellence using the Bariatric Outcomes Longitudinal Database Surgery for Obesity and Related Diseases 6 (2010) 347–355
21. SAS/STAT(R) 9.22 User's Guide, 2009. The SAS Institute, Cary, NC
22. Sczepaniak JP, Owens ML, Garner W. A Simpler Method for Predicting Weight Loss in the First  
Year after Roux-en-Y Gastric Bypass Journal of Obesity  
395 Volume 2012 (2012), Article ID 195251, 5 pages

23. Wood GC, Benotti P, Gerhard GS. A Patient-Centered Electronic Tool for Weight Loss Outcomes after Roux-en-Y Gastric Bypass Journal of Obesity Volume 2014 (2014), Article ID 364941, 7 pages
24. Wise ES, Hocking K, Kavic SM. Prediction of excess weight loss after laparoscopic Roux-en-gastric bypass: data from an artificial neural network Surg Endos 2016, 30:480-8
25. Livhits M, Mercado C, Yermilov I Preoperative predictors of weight loss following bariatric surgery: systematic review. *Obes Surg.* 2012 Jan;22(1):70-89. doi: 10.1007/s11695-011-0472-4.
26. Raisdana B, Slotman G: Cardiopulmonary, Metabolic, and Hepatobiliary Dysfunction Varies by Insurance Status in the Mega-Obese . *Crit Care Med.* 2014. 41: 12 (Suppl.) 542
40527. Adams M, Slotman G: The Effect of Race on the Distribution of Demographics, Body Mass, and Medical Co-Morbidities in Morbid Obesity – An Analysis of 83,059 Patients from the BOLD Database. *Am. J. Gastroenterology.* 2013 108: S479
28. Coupaye M, Sabaté JM, Castel B. Predictive Factors of Weight Loss 1 Year after Laparoscopic Gastric Bypass in Obese Patients. *OBES SURG* (2010) 20:1671–1677
41029. Park JY, Kim YJ. Prediction of diabetes remission in morbidly obese patients after Roux-en-Y gastric bypass. *Obes. Surg.* DOI 10.1007/11695-015-1823-3
30. Våge V, Nilsen RM, Berstad A, Shahzeer Karmali, and Michel Gagner . Predictors for Remission of Major Components of the Metabolic Syndrome After Biliopancreatic Diversion with Duodenal Switch (BPDDS) *OBES SURG* (2013) 23:80–86
41531. Hatoum IJ, Blackstone R, Hunter TD, Francis DM, Steinbuch M, Harris JL, Kaplan LM. Clinical Factors Associated With Remission of Obesity-Related Comorbidities After Bariatric Surgery *JAMA Surg.* 2016; 151(2):130-137

32. Ashrafian H, le Roux CW, Rowland SP. Metabolic surgery and obstructive sleep apnoea: the protective effects of bariatric procedures Thorax doi:10.1136/thx.2010.151225
42033. Gomez J, Davis M, Slotman G. In the super-obese, weight loss and resolution of obesity co-morbidities after bilio-pancreatic bypass/duodenal switch (DS) vary according to health insurance carrier: Medicaid vs Medicare vs Private Insurance vs Self-Pay in 1673 BOLD database patients. Am J Surg 2016 211: 519-524
34. Mustafa El-Hadi, MD, Daniel W. Birch, MD, Richdeep S. Gill, The effect of bariatric surgery on gastroesophageal reflux disease Can J Surg. 2014 57(2): 139–144.
35. Schauer P, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, Aminian A, Pothier CE, Kim E, Nissen SE, Kashyap SR, et.al. N Engl J Med 2014; 370:2002-2013

430

435

**Table 1. Pre-Operative Parameters Screened and Parameters Identified as Weighted Independent Variables for Prognostic Models**

**Pre-Operative Parameters Screened as Potential Independent Variables:**

440	Height (cm)	IVC Filter
	Weight (kg)	Bariatric Procedure Planned
	BMI	Age
	Gender	Abdominal Hernia
	African-American	Alcohol Use
	Asian	Angina
445	Caucasian	Asthma
	Native American	Back Pain
	Hispanic	Cholelithiasis
	Pacific islander/Hawaiian	Mental Health Diagnosis
	Other Race	Congestive Heart Failure
450	Cholecystectomy	Depression
	Cholecystectomy with Common	GERD
	Bile Duct Exploration	Hypertension
	Endoscopic Examination	Liver Disease
	Gastrectomy Partial	Musculoskeletal Pain
455	Gastrectomy Total	Obesity Hypoventilation Syndrome
	Hiatal Hernia Repair	Psychological Impairment
	Liver Biopsy	Pulmonary Hypertension
	Lysis of Adhesions	Stress Urinary Incontinence
	Small Bowel Resection	Tobacco Use
460	Umbilical Hernia Repair	Full Time Employment
	Ventral Hernia Repair	Sex

**Final Independent Variables Used in the SMART Bariatric Models:**

465	Age	Height (cm)
	Abdominal Hernia	Hypertension
	African-American	Operation
	Alcohol Use	Liver Disease
	Angina	Mental Health Diagnosis
	Asthma	Musculoskeletal Pain
	Back Pain	Obesity Hypoventilation Syndrome

470 Congestive Heart Failure  
Caucasian

Psychological Impairment  
Employment

475 Cholelithiasis  
Depression  
GERD

Pulmonary Hypertension  
Stress Urinary Incontinence  
Weight (kg)  
Gender

480

485

490

**Table 2. Modeling and Validation Results for Continuous and Categorical Dependent Variables**

495	<b>Model Fit for Continuous and Categorical Dependent Variables</b>					
	<b>Observation:</b>	<b>2 Months</b>	<b>6 Months</b>	<b>12 Months</b>	<b>18 Months</b>	<b>24 Months</b>
	Number of Patients	120,909	75,130	42,410	15,387	11,014
	<b>Continuous Dependent Variables:</b>					
	(r-squared)					
500	Weight/Weight Loss	0.910	0.813	0.725	0.638	0.61
	<b>Dichotomous Dependent Variables:</b>					
	(ROC/AUC)					
	Cholelithiasis	0.985	0.975	0.967	0.957	0.949
	Diabetes Mellitus	0.956	0.940	0.933	0.930	0.926
505	GERD	0.898	0.860	0.829	0.818	0.804
	Hypertension	0.913	0.891	0.874	0.869	0.858
	Liver Disease	0.963	0.956	0.950	0.940	0.941
	Obstructive	0.887	0.858	0.837	0.841	0.827
	Sleep Anea					
510	Congestive Heart Failure	0.881	0.878	0.883	0.883	0.872
	Abdominal Hernia	0.971	0.960	0.947	0.935	0.921
	Surgeon Follow-up/	0.597	0.600	0.599	0.603	0.620
	Support Group Attendance					



515 Any Adverse Event 0.683 0.683

**Predicted Versus Observed Outcomes from Validation Group Pre-Operative Data Entered into Prognostic Models Built on the Modeling Group**

**Observation: 2 Months 6 Months 12 Months 18 Months 24 Months**

Number of Patients 41,528 25,768 14,527 5,255 3,703

520 **Continuous Dependent Variables:**

Pearson Correlation Coefficient

Weight/Weight Loss 0.959 0.932 0.875 0.837 0.811

**Dichotomous Dependent Variables:**

Cholelithiasis

525 Sensitivity 97.13 94.7 91.78 90.94 86.93  
Specificity 98.83 98.34 97.62 97.42 97.21

Diabetes Mellitus

530 Sensitivity 98.39 74.87 72.14 69.14 60.28  
Specificity 88.59 91.85 91.59 91.36 93.97

GERD

535 Sensitivity 95.12 74.81 49.82 47.32 44.77  
Specificity 81.05 80.27 87.07 87.25 86.65

Hypertension

540 Sensitivity 92.44 92.61 77.91 79.15 79.56  
Specificity 85.21 74.58 80.92 80.02 79.3

Liver Disease

545 Sensitivity 88.55 85.22 84.79 79.39 77.58  
Specificity 99.2 98.86 98.41 98.47 98.05

Obstructive Sleep Apnea

550 Sensitivity 73.99 87.57 64.06 59.05 50.76

	Specificity	93.68	87.64	88.01	89.94	90.95
555	Abdominal Hernia					
	Sensitivity	93.31	90.03	85.99	79.2	75.27
	Specificity	99.56	99.45	99.16	99.27	99.1
560	Congestive Heart Failure					
	Sensitivity	40.35	40.62	37.61	42.47	25
	Specificity	99.84	99.79	99.71	99.68	99.4
565	Post-Operative Surgeon Follow-up and/or Support Group Attendance					
	Sensitivity	0.38	0.05	0.19	0	0.23
	Specificity	99.87	99.98	99.94	99.89	99.9
570	Any Adverse Event					
	Sensitivity		0.52	0.51		
	Specificity		99.92	99.92		
575						
580						

585 **Table 3. Example Output of Prognostic Models Predicting Outcomes for 50 Year-Old Female, 5ft 4in Tall, 320 lbs, with Depression, Diabetes, GERD, Hypertension, and Stress Urinary Incontinence.**

Date:	2 months	6 months	12 months	18 months	24 months	
<b>Weight</b>						
	AGB	292	277	263	254	251
590	BPD/DS	275	230	194	183	182
	LRYGB	277	234	208	200	200
	RYGB	277	235	208	199	198
	SG	280	245	222	217	211

595 **Relative Risk of Having Morbid Obesity Co-Morbidities (%)**

Abdominal Hernia

	AGB	0	1	1	1	1
	BPD/DS	0	2	9	16	13
	LRYGB	0	1	1	1	1
600	RYGB	0	1	2	3	4
	SG					

Congestive Heart Failure

	AGB	0	1	1	1	0
605	BPD/DS	1	1	1	1	1
	LRYGB	1	1	1	1	1
	RYGB	0	1	0	1	0

	SG	1	1	1	1	0
610	Cholelithiasis					
	AGB	1	1	2	2	2
	BPD/DS	14	20	26	31	29
	LRYGB	1	1	2	2	3
	RYGB	1	1	1	2	2
615	SG	1	2	3	4	5
	GERD					
	AGB	38	30	25	25	24
	BPD/DS	47	41	26	31	32
620	LRYGB	36	23	17	18	16
	RYGB	36	28	22	24	25
	SG	41	32	34	25	25
	Diabetes					
625	AGB	23	20	17	15	14
	BPD/DS	21	14	7	7	4
	LRYGB	24	15	10	8	7
	RYGB	24	17	13	11	10
	SG	23	16	11	10	8
630						

Hypertension

	AGB	58	52	43	37	38
635	BPD/DS	39	25	14	14	13
	LRYGB	42	27	19	16	16
	RYGB	48	32	28	29	25
	SG	46	33	24	23	21

Liver Disease

640	AGB	1	1	1	1	1
	BPD/DS	4	5	3	2	3
	LRYGB	1	1	1	1	0
	RYGB	3	2	2	1	2
	SG	1	1	1	1	1

645

Obstructive Sleep Apnea

	AGB	47	45	40	38	35
	BPD/DS	55	45	34	33	31
	LRYGB	48	38	28	26	23
650	RYGB	51	42	32	28	25
	SG	49	42	32	30	26

655

Surgeon Follow-up/Support Group Attendance

	AGB	12	13	11	11	9
	BPD/DS	20	22	19	21	18
660	LRYGB	16	18	16	16	14
	RYGB	16	17	15	14	15
	SG	15	17	14	15	12

665